Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2024-01-10 Declaration of Voting R…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding for 'Nordnet AB (publ)' concerning the instrument 'Aktie SE0020181014'. It explicitly states the 'Reason for major shareholding notification' as 'New share issue' and provides detailed figures for shares and voting rights before and after the transaction, culminating in a new percentage (5.01279%). This structure—reporting changes in ownership thresholds by a significant holder—is characteristic of a Major Shareholding Notification. This aligns with the definition for Code MRQ.
2024-01-10 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding by Avanza Bank Holding AB in Medivir Aktiebolag due to a new share issue (nyemission). This falls under the category of a Major Shareholding Notification, as it reports a significant change in ownership levels crossing regulatory thresholds.
2024-01-10 Swedish
Medivir offentliggör utfallet i företrädesemissionen
Capital/Financing Update Classification · 99% confidence The document is a press release from Medivir AB announcing the final outcome of a rights issue ('företrädesemissionen'). It details the subscription rate (87%), the capital raised (approximately 129 MSEK), the intended use of funds (financing clinical studies), and the timeline for registration and trading of new shares. This content directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2023-12-22 Swedish
Medivir announces the outcome of the rights issue
Capital/Financing Update Classification · 99% confidence The document is a press release titled "Medivir announces the outcome of the rights issue." It details the subscription results (87% subscribed), the proceeds raised (SEK 129 million), the intended use of funds, and the resulting increase in share capital. This content directly relates to a corporate financing activity, specifically a rights issue, which is a form of capital raising. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific financing event.
2023-12-22 English
Medivir publishes prospectus in connection with the rights issue
Capital/Financing Update Classification · 98% confidence The document is titled "Medivir publishes prospectus in connection with the rights issue". It explicitly states that the Swedish language prospectus relating to the Rights Issue has been approved by the Swedish Financial Supervisory Authority and is available on several websites. The core subject is the publication and details (timetable, subscription undertakings) of a prospectus for a rights issue (a capital raising activity). A prospectus is a key document in financing activities. While it announces the availability of the prospectus, the document itself contains substantial detail about the financing terms and commitments, making it more than just a simple 'Report Publication Announcement' (RPA). The content strongly aligns with documents related to fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-12-06 English
Medivir offentliggör prospekt med anledning av företrädesemission
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "Medivir offentliggör prospekt med anledning av företrädesemission" (Medivir publishes prospectus regarding rights issue). It explicitly states that the prospectus has been approved by the Swedish Financial Supervisory Authority (Finansinspektionen) and provides details about the rights issue, subscription period, and commitments. The text itself is an announcement *about* the publication of a prospectus related to a capital raising event (rights issue). Since the document is an announcement detailing the publication of a formal document (the prospectus) and related capital activity, it strongly aligns with the 'Capital/Financing Update' (CAP) category, as it concerns fundraising and capital structure changes. While it mentions the prospectus, the document itself is the announcement of that event, which is a type of financing update. It is not the full 10-K, IR, or a general regulatory filing (RNS), but a specific announcement about a capital action.
2023-12-06 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.